Qi Yang

Qi Yang

Auto-generated profile, based on publicly available information

Qi Yang

Laboratory of Dermatoimmunology, Rui Jin Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
XLXia Li
Xia Li
QYQi Yang
Qi Yang
JZJie Zheng
Jie Zheng
HGHeng Gu
Heng Gu
KCKun Chen
Kun Chen
LZLina Zhang
Lina Zhang
Psoriasis is a chronic, recurrent skin disease requiring long‐term management. Agents that repair the skin's barrier functionareinvaluable additivesin topical treatments of psoriasis. This multicenter, randomized, controlled trial evaluated the efficacy and safety of a linoleic acid‐ceramide‐containing moisturizer (LA‐Cer) for mild‐to‐moderate psoriasis vulgaris. We randomized 178 patients from both northern and southern regions of China into two groups: 81 patients in the control group received mometasone furoate (MF, 0.1%) cream, while MF in combination with LA‐Cer was administered to 86 patients in the treatment group for 4 weeks. The LA‐Cer‐MF group maintained the use of moisturizer after topical glucocorticoid administration. The primary endpoint, Psoriasis Area and Severity Index 50 (PASI 50) response, revealed the superiority of LA‐Cer‐MF with lower relapse rates at week 8. The use of the LA‐Cer‐containing moisturizer as maintenance therapy resulted in a continuous improvement in the clinical state in terms of body surface area, PASI, investigators' assessment of skin dryness and desquamation, and Physician Global Assessment of Psoriasis score, and in thepatients' quality of life. Thus, the LA‐Cer‐containing moisturizer is a promising agent to prevent and treat psoriasis as it enhances the therapeutic effect induced by topical glucocorticoids and delays relapse.

1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
LCLihong Chen
Lihong Chen
QYQi Yang
Qi Yang
HWHailun Wang
Hailun Wang
SCSzeman Cheung
Szeman Cheung
LZLi Zhang
Li Zhang
XLXia Li
Xia Li
Background: Psoriasis is a systemic inflammatory disease frequently accompanied by cardiometabolic comorbidities. Whether baseline lipid status influences clinical response to interleukin‐17A blockade remains insufficiently defined. Objective: To evaluate the association between baseline low‐density lipoprotein cholesterol (LDL) and week‐16 clinical response to secukinumab in patients with moderate‐to‐severe plaque psoriasis and to describe outcomes under 150‐mg and 300‐mg dosing regimens in real‐world practice. Methods: We performed a single‐center retrospective cohort study including 325 patients with moderate‐to‐severe plaque psoriasis who received secukinumab for at least 16 weeks. Patients received either 150 mg or 300 mg secukinumab at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. The primary outcome was achievement of at least 75% improvement in Psoriasis Area and Severity Index (PASI75) at week 16. Propensity score weighting was used to reduce baseline imbalance between dosing groups. The primary association was estimated using multivariable logistic regression with baseline LDL modeled continuously and adjustment for multiple factors. Missing LDL was evaluated using measured‐versus‐missing comparisons and multiple imputation as a sensitivity analysis. Results: After inverse probability weighting, baseline demographic and disease severity variables were generally balanced between dose groups, although residual imbalance in selected laboratory variables remained. Week‐16 PASI75 response did not differ significantly between the 150‐mg and 300‐mg groups after adjustment, while early PASI90 response was more frequent in the 300‐mg group and week‐16 PASI100 response was more frequent in the 150‐mg group. Baseline LDL was inversely associated with PASI75 response at week 16 (ORs per 1 mmol/L increase, 0.696, and 95% CI: 0.497–0.976), and further multiple imputation as a sensitivity analysis confirmed the adjusted OR was 0.718 (95% CI: 0.516–0.999, p = 0.049). Patients with low LDL had a higher PASI75 response rate than those with high LDL (85.2% vs 66.7%). In the 300‐mg subgroup, high LDL was associated with lower PASI75 and PASI90 response rates. Secukinumab reduced selected inflammatory and metabolic biomarkers, including CRP, ESR, SCC, glucose, and triglycerides, but LDL and HDL did not show significant improvement over 16 weeks. Limitations: This was a retrospective, single‐center study with potential residual confounding, missing baseline LDL, a relatively small high‐LDL subgroup, retrospectively defined multiplicity families, and the absence of prospective validation. Conclusions: Higher baseline LDL was associated with a lower probability of achieving week‐16 PASI75 after covariate adjustment. LDL should be considered a hypothesis‐generating candidate factor of secukinumab response and may help identify patients who require closer clinical and cardiometabolic monitoring during biologic therapy.